Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US-12180196-B2 · Dec 31, 2024 · US
US9422278B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9422278-B2 |
| Application number | US-201514631250-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 25, 2015 |
| Priority date | Nov 3, 2010 |
| Publication date | Aug 23, 2016 |
| Grant date | Aug 23, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This document discloses molecules having the following formula (“Formula One”): and processes related thereto.
Opening claim text (preview).
We claim: 1. A composition comprising a molecule according to wherein (a) A is (b) R1 is H; (c) R2 is H; (d) R3 is H; (e) R4 is H, Cl, Br, unsubstituted C 1 -C 6 alkyl, or unsubstituted C 2 -C 6 alkenyl; (f) R5 is H or Cl; (g) R6 is H, substituted or unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, unsubstituted C 3 -C 10 cycloalkyl, (C 1 -C 6 alkyl)OC(═O)(C 1 -C 6 alkyl), or C 1 -C 6 alkyl-(C 3 -C 10 cyclohaloalkyl), wherein each said R6, which is substituted, has one or more substituents selected from the group consisting of CN and C 3 -C 10 cycloalkyl; (h) R7 is O or S; (i) R8 is substituted or unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 3 -C 10 cycloalkyl, OR9, N(R9) 2 , or SR9, wherein each said R8, which is substituted, has one or more substituents selected from the group consisting of F, Cl, Br, I, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkyloxy, N(R9)S(O) n R9, OR9, and S(O) n R9; (j) R9 is (each independently) H, substituted or unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, S(O) n C 1 -C 6 alkyl, N(C 1 -C 6 alkyl) 2 , wherein each said R9, which is substituted, has one or more substituents selected from the group consisting of F, Cl, Br, I, and S(O) n C 1 -C 6 alkyl; (k) n is 0, 1, or 2; and (l) X is CR n1 where R n1 is H or F. 2. A composition according to claim 1 wherein said molecule is one of the following molecules Com- pound No. Structure 32 55 57 58 59 60 64 67 70 73 74 75 76 79 80 86 90 95 97 98
Antibacterial agents · CPC title
Ectoparasiticides, e.g. scabicides · CPC title
Antiparasitic agents · CPC title
containing the group >N—CO—N< directly attached to at least one heterocyclic ring; Thio analogues thereof · CPC title
1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.